<http://schema.org/description>
"GlaxoSmithKline hands back rights to DMD program to Prosensa, which could affect rival Sarepta Therapeutics."^^<http://www.w3.org/2001/XMLSchema#string>
<http://www.fool.com/investing/general/2014/01/13/gsk-gives-drisapersen-back-to-prosensa-rna.aspx>